Mogrify has developed a proprietary suite of technology platforms that enable systematic identification of the key transcriptomic and epigenetic switches that drive the speed, efficiency and maintenance of cell reprogramming for the development of cell therapies and in vivo reprogramming therapies.
MOGRIFY® is a direct cellular reprogramming technology that utilizes a systematic big-data approach (Rackham et al., Nature Genetics, 2016) that deploys next-generation sequencing and gene regulatory data to enable the prediction of the transcription factors (or small molecules) required to produce (ex vivo or in vivo) any target cell type from any source cell type.
epiMOGRIFY is a cell identity platform, which leverages epigenetic data to identify optimal combinations of transcription factors or growth factors required to maintain cell identity and epigenetically support the conversion of cells in chemically defined media.
These platforms are being deployed to develop scalable ex vivo cell therapies and in vivo reprogramming therapies for immuno-oncology, ophthalmology and other disease areas with a high unmet clinical need.
Learn more about our technology: mogrify.co.uk/science/mogrify/